When was MeMed founded?

MeMed was founded in 2009 and raised its 1st funding round 6 years after it was founded.

Where is MeMed located?

MeMed is headquartered in Tirat Carmel, Israel. It is registered at 7 CORONATION ROAD, DEPHNA HOUSE, LAUNCHESE #105,LONDON,UNITED KINGDOM,NW10 7PQ.

Who is the current CEO of MeMed?

Eran Eden of MeMed. They have also founded 1 company.

How many employees does MeMed have?

As of Jul 31, 2026, the latest employee count at MeMed is 98.

Is MeMed a funded company?

MeMed is a funded company, having raised a total of $163M across 10 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 23, 2015.

When was the latest funding round of MeMed?

MeMed's latest funding was a $***** Series D round on Jan 10, 2022, with participation from 11 investors.

Where does MeMed rank among its competitors?

MeMed ranks 2nd amongst 369 active competitors, of which 83 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Daye, which secured $576K in Nov, 2025.

Who are the top competitors of MeMed?

MeMed's top competitors include Adaptive Biotechnologies, HaystackAnalytics and Huwel Life. Among them, Daye secured the most recent funding round in November, 2025.

MeMed - 2026 Company Profile, Team, Funding & Competitors

MeMed is a series D company based in Tirat Carmel (Israel), founded in 2009 by Eran Eden. It operates as a Provider of machine learning based diagnostic solutions for infectious diseases. MeMed has raised $163M in funding from investors like Phoenix Insurance Group, Ping An and Poalim Capital Markets. The company has 369 active competitors, including 83 funded and 53 that have exited. Its top competitors include companies like Adaptive Biotechnologies, HaystackAnalytics and Huwel Life.

Company Details

MeMed Diagnostics provides machine learning-based diagnostic solutions for infectious diseases. The company's lead product ImmunoXpert, distinguishes between bacterial and viral infections based on the patient’s immune response in-vitro diagnostic test. The company also offers ImmunoPoC, a device for distinguishing between bacterial and viral infections at the point-of-care. The company also provides its immunoassay platform MeMed Key. Its solution also diagnoses infections inaccessible for direct pathogen sampling and avoids false alarms due to the presence of non-pathogenic bacteria and viruses.

Website: www.me-med.com/
Social
Email ID: *****@me-med.com
Phone Number: +972 **********, +1 **********
Registered Address: 7 CORONATION ROAD, DEPHNA HOUSE, LAUNCHESE #105,LONDON,UNITED KINGDOM,NW10 7PQ

Key Metrics

Founded Year

2009

Location

Tirat Carmel, Israel

Stage

Series D

Total Funding

$163M in 10 rounds

Latest Funding Round

Series D, Jan 10, 2022, $*****

Investors

Phoenix Insurance Group & 24 more

Ranked

2^nd among 369 active competitors

Employee Count

98 as on Jul 31, 2026

Similar Companies

Adaptive Biotechnologies & 428 more

View MeMed's full profile

MeMed is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
MEMEDS LTD CIN: 15026415 , United Kingdom, Active	Jul 24, 2023	-	-

MeMed has raised a total funding of $163M over 10 rounds. Its first funding round was on Jul 23, 2015. Its latest funding round was a Series D round on Jan 10, 2022 for $*****. 11 investors participated in its latest round. MeMed has 23 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of MeMed:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 10, 2022	8943483	Series D	3520147	5372874	9045434	9502940
Jan 01, 2020	7500065	Grant (prize money)	2967981	7773545	7299409	Europa
Nov 13, 2019	8416849	Grant (prize money)	9891167	1109083	7911514	European Union

Access funding benchmarks and valuations. Sign up today!

View details of MeMed's funding rounds and investors

The founders of MeMed is Eran Eden. Eran Eden is the CEO of MeMed.

Here are the details of MeMed's key team members:

Eran Eden: Co-Founder & CEO of MeMed.

View details of MeMed's Founder profiles and Board Members

MeMed's employee count trend

MeMed has 98 employees as of Jul 26. Here is MeMed's employee count trend over the years:

Uncover MeMed's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MeMed include Adaptive Biotechnologies, HaystackAnalytics and Huwel Life. Here is the list of Top 10 competitors of MeMed, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Adaptive Biotechnologies 2009, Seattle (United States), Public	Provider of clinical diagnostics, and drug discovery for immune diseases	$419M	Viking Global Investors, Matrix & 21 others	72/100
2nd	MeMed 2009, Tirat Carmel (Israel), Series D	Provider of machine learning based diagnostic solutions for infectious diseases	$163M	Western Technology Investment, La Maison Partners ... & 23 others	69/100
3rd	HaystackAnalytics 2018, Mumbai (India), Seed	Provider of genomics technology for personalized clinical decisions	$17.3M	STRIVE, Sun Pharma & 33 others	67/100
4th	Huwel Life 2015, Hyderabad (India), Series A	Molecular diagnostic solutions and products for the healthcare industry	$5.74M	Bartronics, BIRAC & 3 others	59/100
5th	Karius 2014, Redwood City (United States), Series C	Provider of diagnostics for identifying infectious diseases using microbial DNA	$315M	Khosla Ventures, Gilde Healthcare & 16 others	58/100
6th	Mylab 2016, Pune (India), Seed	Developer of diagnostic kits for pathogen detection and viral load monitoring	-	Rising Sun Holdings, Zydus Life & 10 others	57/100
7th	Seegene Technologies 2000, Seoul (South Korea), Public	Provider of advanced molecular diagnostics solutions	-	IMM Investment, Songhyun Investment & 3 others	56/100
8th	Daye 2018, London (United Kingdom), Series A	Manufacturer of period care products and provider of health tests	$19.2M	Salica Investments, Kindred Capital & 24 others	56/100
9th	Clear Labs 2014, Menlo Park (United States), Series D	Provider of food safety technologies for the identification of pathogens	$171M	Menlo Ventures, Redmile Group & 26 others	56/100
10th	Quantamatrix 2010, Seoul (South Korea), Public	Multiplexed platform for disease daignosis	$198K	Treatment Action Group, Shield Investment ... & 6 others	55/100